Natera, Inc. (NTRA)
$
157.73
-0.32 (-0.20%)
Key metrics
Financial statements
Free cash flow per share
0.6322
Market cap
21.1 Billion
Price to sales ratio
11.5241
Debt to equity
0.1479
Current ratio
3.8733
Income quality
-0.8069
Average inventory
47.6 Million
ROE
-0.1829
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services worldwide. The company reported a net loss of -$190,426,000.00 indicating challenges in its operations. Additionally, the net total of other income and expenses is $32,563,000.00 reflecting non-core financial activities. Despite this, the company reported an income before tax of -$189,731,000.00 showcasing its pre-tax profitability. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. The EBITDA is -$148,078,000.00 a key indicator of the company's operational profitability. Natera offers a variety of diagnostic tests, including Panorama, a non-invasive prenatal test, and Vistara for single-gene mutations, among others. The company engages in direct sales as well as through a network of approximately 100 laboratory and distribution partners. Collaborations with organizations such as BGI Genomics Co., Ltd. for NGS-based genetic testing assays and Foundation Medicine, Inc. for personalized circulating tumor DNA monitoring assays further highlight its focus on enhancing diagnostic capabilities. Founded in 2003 and based in Austin, Texas, Natera was formerly known as Gene Security Network, Inc. before rebranding in 2012. The stock is reasonably priced at $158.05 appealing to a broad range of investors. It has a high average trading volume of 1,575,422.00 indicating strong liquidity within the market. With a mid-range market capitalization of $21,537,558,310.00 the company is a steady performer in its field. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it continues to expand its portfolio of genetic testing services. Natera's focus on improving health outcomes through advanced diagnostics positions it as a critical component of the evolving healthcare landscape.
Is Natera, Inc. (NTRA) a good investment?
Investing in Natera, Inc. (NTRA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Natera, Inc. (NTRA)'s stock forecast?
Analysts predict Natera, Inc. stock to fluctuate between $92.14 (low) and $183 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Natera, Inc.'s market capitalization?
As of 2025-05-30, Natera, Inc.'s market cap is $21,537,558,310, based on 136,547,000 outstanding shares.
How does Natera, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Natera, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Natera, Inc. (NTRA) stock?
To buy Natera, Inc. (NTRA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for NTRA. Place an order (Market, Limit, etc.).
What is the best time to invest in Natera, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Natera, Inc. perform in the last earnings report?
Revenue: $1,696,911,000 | EPS: -$1.53 | Growth: -59.52%.
Where can I find Natera, Inc.'s investor relations reports?
Visit https://www.natera.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Natera, Inc.?
You can explore historical data from here
What is the all-time high and low for Natera, Inc. stock?
All-time high: $183 (2025-01-13) | All-time low: $26.10 (2022-03-09).
What are the key trends affecting Natera, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analys.
seekingalpha.com
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue.
zacks.com
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
seekingalpha.com
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
zacks.com
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
seekingalpha.com
Natera, Inc. (NASDAQ:NTRA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Alexey Aleshin - GM Oncology, CMO Solomon Moshkevich - President, Clinical Diagnostics John Fesko - President and Chief Business Officer Conference Call Participants Doug Schenkel - Wolfe Research Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Baird Daniel Brennan - TD Cowen Dan Leonard - UBS Subbu Nambi - Guggenheim Operator Welcome everyone to Natera's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
zacks.com
Natera (NTRA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.64 per share a year ago.
businesswire.com
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients with stage I-III NSCLC with resectable or unresectable disease in the surveillance setting. It expands upon preexistin.
zacks.com
From a technical perspective, Natera (NTRA) is looking like an interesting pick, as it just reached a key level of support. NTRA recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
See all news
